Trading Signals: SGEN Stock Price Prediction and Forecast (Fri. May. 30, 2003 - Wed. Dec. 13, 2023)(Seattle Genetics, Inc.)
| SGEN latest price $26.8800 (0%) ($26.6800 - $27.2500) on Tue. Feb. 26, 2013. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2% (three month average) | RSI | 26 | Latest Price | $26.8800(0%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | SGEN declines -0.6% a day on average for past five trading days. | Weekly Trend | SGEN declines -4.9% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support SGEN advance at 0% a week (0% probability) IWM(32%) QQQ(32%) SPY(32%) XLK(28%) XLY(26%) | Factors Impacting SGEN price | SGEN will decline at least -1% in a week (0% probabilities). TLT(-10%) SHY(-4%) IGOV(-3%) TIP(-1%) GLD(2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1% (StdDev 2%) | Hourly BBV | 0 () | Intraday Trend | -0.6% | | | |
|
1 - 5 Day Possible Target | $18.93(-29.58%) | Resistance Level | $28.56 | 5 Day Moving Average | $27.06(-0.67%) | 10 Day Moving Average | $27.48(-2.18%) | 20 Day Moving Average | $28.56(-5.88%) | To recent high | -11.6% | To recent low | 17% | Market Cap | $4.673b | | | | Seattle Genetics, Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. |